| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.8 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.8 |